Lumiracoxib: A viewpoint

Drugs

Volumn 64, Issue 19, 2004, Pages 2247-2248

  Tannenbaum, Hyman ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULFONAMIDE; SULFONE; VALDECOXIB;

BLEEDING; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; NOTE; OBSTRUCTION; OSTEOARTHRITIS; PAIN; PERFORATION; PROPHYLAXIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH ULCER;

EID: 6044237895     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464190-00010     Document Type: Note

References (11)

1. Marshall PJ, Berry C, Wasvary J, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2 [abstract no. SAT0013]. Ann Rheum Dis 2002; 61 Suppl. 1: 259
2. Tannenbaum H, Berenbaum F, Reginster JY, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis. Epub 2004 Feb 27
3. Bitner M, Kattenhorn J, Hatfield C, et al. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. Int J Clin Pract 2004 Apr; 58 (4): 340-5
4. Pavelka K, Nayiager S, Kivitz A, et al. Efficacy and tolerability of lumiracoxib in the treatment of rheumatoid arthritis: a 13-week, randomized, double-blind study [abstract no. FRI10107]. Ann Rheum Dis 2004 Jul; 63 Suppl. 1: 280
5. Kivitz AJ, Nayiager S, Schimansky T, et al. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004 Jun 1; 19(11): 1189-98
6. Hawkey CJ, Karateev D, Codreanu C, et al. Improved upper gastrointestinal (UGI) safety and tolerability of a new coxib, COX189 compared with ibuprofen in osteoarthritis patients [abstract no. THU0226]. Ann Rheum Dis 2002; 61 Suppl. 1: 126
7. Schnitzer TM, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004 Aug 21; 364 (9435): 665-74
8. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004 Aug 21; 364 (9435): 675-84
9. Schnitzer TJ, Beier J, Geusens P, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2004; 51 (4): 549-57
10. Geusens P, Alten R, Rovensky J, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: results of a randomized double-blind study [abstract no. 544]. Arthritis Rheum 2003; 48 (9 Suppl.): 242
11. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 2000 Nov 23; 343 (21): 1520-8